1 Min Read
March 2 (Reuters) - Sierra Oncology Inc
* Sierra Oncology reports 2016 year-end results
* Sierra Oncology Inc -" existing cash and cash equivalents will be sufficient to fund our current operating plans through approximately mid-2019"
* Sierra Oncology Inc - qtrly net loss per share attributable to common stockholders $0.30 Source text for Eikon: Further company coverage: